Sort
25,944 grants matching “neurodegeneration”
Regulation Of Intracellular Iron Metabolism
$1,328,253Tracey A. Rouault · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2022 · HD
Anti-Viral therapy in Alzheimer's disease
$1,327,757Davangere P Devanand · Columbia University Health Sciences · R01 · FY2017 · AG
Behavioral and Neural Plasticity in the Aged
$1,325,913University Of California Irvine · P01 · FY2003 · AG
Molecular Basis for the Pathogenesis of Murine Retroviruses
$1,324,542Sandra K Ruscetti · Basic Sciences · Z01 · FY2007 · CA
Theraupeutic Candidates for Huntington's Disease: From Lead to IND
$1,324,509Aleksey Gregory Kazantsev · Massachusetts General Hospital · U01 · FY2011 · NS
Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease
$1,322,759Satheesh B Ravula · Epigen Biosciences, Inc. · R44 · FY2020 · AG
Longitudinal Relationships Among Sleep, Cognition and Alzheimer's Disease Biomarkers: Discerning Causal Associations, Mediators and Susceptibility
$1,321,590Susan S Redline · Brigham And Women'S Hospital · R01 · FY2024 · AG
Secondary analysis of functional MRI and resting state connectivity in white matter
$1,320,938John C Gore · Vanderbilt University Medical Center · RF1 · FY2021 · MH
Study of Selective Cell and System Vulnerability in Alzheimer's Disease
$1,320,382Yun Li · Univ Of North Carolina Chapel Hill · R01 · FY2024 · AG
Understanding the dynamic interactions between tau pathology and microgliamediated inflammation in Alzheimer's Disease
$1,319,736Ajay Gupta · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · AG
Single nucleus gene expression in moderate and compulsive drug self-administration in a rodent model of HIV
$1,318,918Pietro P Sanna · Scripps Research Institute, The · U01 · FY2023 · DA
Enzymes of O-GlcNAc cycling linked to type-2 diabetes and neurodegeneration
$1,318,649John A. Hanover · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Staging Alzheimer disease with blood-based biomarkers
$1,318,533Suzanne Elizabeth Schindler · Washington University · R01 · FY2022 · AG
Tau and Neurodegeneration II: A therapeutic target
$1,318,457Dennis William Dickson · Mayo Clinic Jacksonville · P01 · FY2008 · AG
Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects
$1,318,445Ilya Ilin · General Biophysics, Llc · R42 · FY2023 · AG
Cell Specific Perturbations of the Proteome in Alzheimer's Disease
$1,317,961John Robert Yates · Scripps Research Institute, The · R01 · FY2023 · AG
Cell Specific Perturbations of the Proteome in Alzheimer's Disease
$1,317,961John Robert Yates · Scripps Research Institute, The · R01 · FY2022 · AG
Cell Specific Perturbations of the Proteome in Alzheimer's Disease
$1,317,961John Robert Yates · Scripps Research Institute, The · R01 · FY2024 · AG
Cell Specific Perturbations of the Proteome in Alzheimer's Disease
$1,317,961John Robert Yates · Scripps Research Institute, The · R01 · FY2021 · AG
MAYO ALZHEIMERS DISEASE RESEARCH CENTER
$1,316,900Mayo Clinic Coll Of Medicine, Rochester · P50 · FY2000 · AG
EXCITATORY TRANSMITTERS, MEMORY, AGING AND DEMENTIA
$1,316,762Washington University · P01 · FY2001 · AG
Tau and Neurodegeneration II: A therapeutic target
$1,316,477Dennis William Dickson · Mayo Clinic Jacksonville · P01 · FY2007 · AG
Molecular substrates of aging and neuron death
$1,316,145John Q. Trojanowski · University Of Pennsylvania · P01 · FY2008 · AG
Developing a novel EEG-based index for evaluating amyloid and tau burden in Alzheimer's Disease
$1,314,973Che Lucero · Spark Neuro Inc. · R44 · FY2023 · AG
Anti-Viral therapy in Alzheimer's disease
$1,312,757Davangere P Devanand · Columbia University Health Sciences · R01 · FY2018 · AG